WO2012136133A1 - Utilisation de composés de a-nor-5alpha-androstane pour préparer un médicament anti-tumeur maligne - Google Patents

Utilisation de composés de a-nor-5alpha-androstane pour préparer un médicament anti-tumeur maligne Download PDF

Info

Publication number
WO2012136133A1
WO2012136133A1 PCT/CN2012/073490 CN2012073490W WO2012136133A1 WO 2012136133 A1 WO2012136133 A1 WO 2012136133A1 CN 2012073490 W CN2012073490 W CN 2012073490W WO 2012136133 A1 WO2012136133 A1 WO 2012136133A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
carbon
unsubstituted
cancer
substituted
Prior art date
Application number
PCT/CN2012/073490
Other languages
English (en)
Chinese (zh)
Inventor
李瑞麟
曹振全
谌志华
傅大熙
陈雅君
Original Assignee
上海奥奇医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44774943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012136133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 上海奥奇医药科技有限公司 filed Critical 上海奥奇医药科技有限公司
Publication of WO2012136133A1 publication Critical patent/WO2012136133A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de composés de A-nor-5alpha-androstane pour préparer un médicament anti-tumeur maligne. Des essais in vitro montrent que les composés de A-nor-5alpha-androstane ont une activité pour inhiber différentes cellules tumorales in vitro, et un taux d'inhibition de croissance moyen de plus de 85 %. Des essais in vivo montrent que les composés de A-nor-5alpha-androstane peuvent inhiber différentes tumeurs, telles qu'un cancer du côlon, un cancer hépatique, un cancer du poumon, un cancer du sein, un mélanome B16, etc. L'invention concerne en outre la composition de médicament anticancéreux et le procédé pour traiter un cancer.
PCT/CN2012/073490 2011-04-08 2012-04-01 Utilisation de composés de a-nor-5alpha-androstane pour préparer un médicament anti-tumeur maligne WO2012136133A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110088946.4 2011-04-08
CN201110088946A CN102218069B (zh) 2011-04-08 2011-04-08 A-失碳-5α-雄甾烷化合物在制备抗恶性肿瘤药物中的应用

Publications (1)

Publication Number Publication Date
WO2012136133A1 true WO2012136133A1 (fr) 2012-10-11

Family

ID=44774943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/073490 WO2012136133A1 (fr) 2011-04-08 2012-04-01 Utilisation de composés de a-nor-5alpha-androstane pour préparer un médicament anti-tumeur maligne

Country Status (2)

Country Link
CN (1) CN102218069B (fr)
WO (1) WO2012136133A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015169173A1 (fr) 2014-05-08 2015-11-12 Shanghai Institute Of Planned Parenthood Research Compositions d'anordrine et méthodes de traitement de maladies
US20170216313A1 (en) * 2014-09-29 2017-08-03 Yajun CHEN ORAL FORMULATION OF A-NOR-5a ANDROSTANE COMPOUND
US20200289527A1 (en) * 2017-10-13 2020-09-17 Shanghai Ao Qi Medical Technology Co., Ltd. FORMULATION CONTAINING A-DECARBONIZED-5a ANDROSTANE COMPOUND FOR INCREASING WHITE BLOOD CELL AND USE THEREOF
EP3949970A4 (fr) * 2019-04-04 2022-12-21 Shanghai Ao Qi Medical Technology Co., Ltd. Utilisation combinée d'un médicament composé a-nor-5alpha androstane et d'un médicament anti-cancéreux

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019041078A1 (fr) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. Synthèse asymétrique et utilisations de composés dans des traitements de maladies
CN114685597A (zh) * 2020-12-30 2022-07-01 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物的多晶型物
CN115322239B (zh) * 2022-07-20 2023-12-01 湖北葛店人福药业有限责任公司 一种从双炔失碳酯母液物中回收双酮的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001120A (en) * 1989-05-10 1991-03-19 Natural Pharmacia International, Inc. Use of A-Nor-steroids as malignant cells growth inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114610C (zh) * 2000-06-26 2003-07-16 上海科学院 有治疗前列腺增生药效的化合物及制备方法
CN1172950C (zh) * 2001-04-29 2004-10-27 上海市计划生育科学研究所 一种有抗生育作用的化合物及制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001120A (en) * 1989-05-10 1991-03-19 Natural Pharmacia International, Inc. Use of A-Nor-steroids as malignant cells growth inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GU, JIAN ET AL.: "Comparison of antitumor effect of a-anordrin and its metabolite AF-45", TUMOR, vol. 14, no. 2, March 1994 (1994-03-01), pages 66 - 69, XP055235994 *
LI, RUILIN ET AL.: "Synthesis and Antifertility Activity of A-Nor Steroidal Compounds", CHINESE JOURNAL OF PHARMACEUTICALS., vol. 17, no. 9, September 1986 (1986-09-01), pages 20 - 29 *
MA, ZHONGCAI ET AL.: "Antiangiogenic effect of alpha-anordrin in vitro and in vivo.", ACTA PHARMACOL SIN., vol. 21, no. 10, October 2000 (2000-10-01), pages 939 - 944 *
MA, ZHONGCAI ET AL.: "The Inhibitory Effect of a-Anordrin and Other Drugs on the Growth of Swarm Rat Chondrosarcoma", CHINESE JOURNAL OF CLINICAL ONCOLOGY., vol. 26, no. 10, October 1999 (1999-10-01), pages 771 - 775 *
WANG, KEFANG ET AL.: "Review on Anordrin's Working Mechanism and Clinic Application", CHINESE JOURNAL OF FAMILY PLANNING., no. 2, February 2005 (2005-02-01), pages 127 - 128 *
ZHANG LI ET AL.: "The Effects of a-Anordrin (a-ANO) on the Growth of Androgen Dependent Human Prostate Cancer Cell Line LNCaP", JOURNAL OF FUJIAN MEDICAL UNIVERSITY., vol. 42, no. 3, May 2008 (2008-05-01), pages 208 - 211 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015169173A1 (fr) 2014-05-08 2015-11-12 Shanghai Institute Of Planned Parenthood Research Compositions d'anordrine et méthodes de traitement de maladies
EP3139928A4 (fr) * 2014-05-08 2017-12-13 Shanghai Institute Of Planned Parenthood Research Compositions d'anordrine et méthodes de traitement de maladies
US10231978B2 (en) 2014-05-08 2019-03-19 Shanghai Institute Of Planned Parenthood Research Anordrin compositions and methods for treating diseases
US10857158B2 (en) 2014-05-08 2020-12-08 Zhejiang Jiachi Development Pharmaceuticals Ltd Anordrin compositions and methods for treating diseases
US11911397B2 (en) 2014-05-08 2024-02-27 Zhejiang Jiachi Development Pharmaceuticals Ltd Anordrin compositions and methods for treating diseases
US20170216313A1 (en) * 2014-09-29 2017-08-03 Yajun CHEN ORAL FORMULATION OF A-NOR-5a ANDROSTANE COMPOUND
JP2017530162A (ja) * 2014-09-29 2017-10-12 ヤージュン チェン Ａ−ノル−５αアンドロスタン化合物の経口投与製剤
US10537583B2 (en) 2014-09-29 2020-01-21 Yajun CHEN Oral formulation of A-nor-5α androstane compound
US20200289527A1 (en) * 2017-10-13 2020-09-17 Shanghai Ao Qi Medical Technology Co., Ltd. FORMULATION CONTAINING A-DECARBONIZED-5a ANDROSTANE COMPOUND FOR INCREASING WHITE BLOOD CELL AND USE THEREOF
EP3949970A4 (fr) * 2019-04-04 2022-12-21 Shanghai Ao Qi Medical Technology Co., Ltd. Utilisation combinée d'un médicament composé a-nor-5alpha androstane et d'un médicament anti-cancéreux

Also Published As

Publication number Publication date
CN102218069A (zh) 2011-10-19
CN102218069B (zh) 2012-09-26

Similar Documents

Publication Publication Date Title
WO2012136133A1 (fr) Utilisation de composés de a-nor-5alpha-androstane pour préparer un médicament anti-tumeur maligne
WO2017162108A1 (fr) Complexe de pillararène, son procédé de préparation, composition pharmaceutique et utilisation correspondantes
CN110981870B (zh) 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途
WO2017198194A1 (fr) Acide boronique et composé ester borate et ses applications
WO2012000421A1 (fr) Utilisation de dérivés de gossypol lors de la préparation de médicaments antitumoraux
EP2924042A1 (fr) Composé bis- -carboline et procédé de préparation, composition pharmaceutique et utilisation associée
CN102895670A (zh) 水溶性分子靶向卟吩光敏剂及其制备方法
JP2001139476A (ja) 癌を含めた悪性新生物に用いる抗悪性腫瘍剤
WO2017101789A1 (fr) Composé ayant un effet anticancéreux, son procédé de préparation et application
WO2016119643A1 (fr) Composé contenant une structure de noyau d'acide indolacétique et son utilisation
WO2010081266A1 (fr) Utilisation nouvelle de la tétrahydropalmatine
CN104177377B (zh) 3位双胺β-咔啉碱类化合物、其制法和其药物组合物与用途
JP2018513130A (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
WO2021120874A1 (fr) Sensibilisateur de médicament antitumoral à base de n-(3-hydroxypyridine-2-carbonyl)glycine et son utilisation
JP2013536204A (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
CN106822129A (zh) 苦豆碱衍生物在制备治疗肿瘤的药物中的应用
WO2014201587A1 (fr) Substance possédant une activité inhibitrice des tyrosine kinases, son procédé de préparation et son utilisation
CN110590778B (zh) 3，10二对甲氧基苯基6，12二氮杂四高立方烷类化合物及合成方法和药物组合物
WO2008154801A1 (fr) Dérivé d'acide trans-cinnamique, son procédé de préparation et son utilisation
CN104225611B (zh) 达沙替尼与非线性构型聚乙二醇的结合物
CN103980341B (zh) 一种氨基酸丹参酮酚酯衍生物及其制备方法
TWI669121B (zh) Compound for the treatment of cancer
CN103012394B (zh) 一种罗丹宁衍生物及其制备方法
WO2019233366A1 (fr) Antagoniste sélectif du récepteur a2a
KR20210150470A (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12767552

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12767552

Country of ref document: EP

Kind code of ref document: A1